Five-year overall survival (OS) and OS by tumour response measures from the phase III HIMALAYA study of tremelimumab plus durvalumab in unresectable hepatocellular carcinoma (uHCC) Meeting Abstract
| Authors: | Rimassa, L.; Chan, S. L.; Sangro, B.; Lau, G.; Kudo, M.; Breder, V.; Varela, M.; Crysler, O.; Bouattour, M.; Dao, V. T.; Faccio, A.; Furuse, J.; Jeng, L. B.; Kang, Y. K.; Kelley, R. K.; Paskow, M. J.; Makowsky, M.; Ran, D.; Negro, A.; Abou-Alfa, G. K. |
| Abstract Title: | Five-year overall survival (OS) and OS by tumour response measures from the phase III HIMALAYA study of tremelimumab plus durvalumab in unresectable hepatocellular carcinoma (uHCC) |
| Meeting Title: | ESMO Congress 2024 |
| Journal Title: | Annals of Oncology |
| Volume: | 35 |
| Issue: | Suppl. 2 |
| Meeting Dates: | 2024 Sep 13-17 |
| Meeting Location: | Barcelona, Spain |
| ISSN: | 0923-7534 |
| Publisher: | Oxford University Press |
| Date Published: | 2024-09-01 |
| Start Page: | S656 |
| Language: | English |
| ACCESSION: | WOS:001326612901251 |
| DOI: | 10.1016/j.annonc.2024.08.1007 |
| PROVIDER: | wos |
| Notes: | Meeting Abstract: 947MO -- Source: Wos |
